Millennium Management
SRPT icon

Millennium Management’s Sarepta Therapeutics SRPT Stock Holding History

Millennium Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,000
Closed -$851K – 6378
2024
Q4 		$851K Buy
7,000
+5,300
+312% +$650K ﹤0.01% 4337
2024
Q3 		$212K Buy
+1,700
New +$235K ﹤0.01% 5417
2024
Q2 		– Sell
-66,400
Closed -$8.6M – 6502
2024
Q1 		$8.6M Sell
66,400
-50,500
-43% -$6.19M ﹤0.01% 2335
2023
Q4 		$11.3M Sell
116,900
-226,600
-66% -$21.7M ﹤0.01% 2065
2023
Q3 		$41.6M Buy
343,500
+331,800
+2,836% +$37.5M 0.02% 832
2023
Q2 		$1.34M Sell
11,700
-63,300
-84% -$8.16M ﹤0.01% 3808
2023
Q1 		$10.3M Buy
+75,000
New +$9.73M 0.01% 1935
2020
Q2 		– Sell
-6,600
Closed -$646K – 4577
2020
Q1 		$646K Buy
+6,600
New +$754K ﹤0.01% 2731
2019
Q2 		– Sell
-24,800
Closed -$2.96M – 4424
2019
Q1 		$2.96M Sell
24,800
-225,200
-90% -$29M ﹤0.01% 2132
2018
Q4 		$27.3M Buy
+250,000
New +$31.3M 0.04% 569
2017
Q4 		– Sell
-30,000
Closed -$1.36M – 4062
2017
Q3 		$1.36M Buy
+30,000
New +$1.2M ﹤0.01% 2365
2017
Q1 		– Sell
-100,000
Closed -$2.74M – 3818
2016
Q4 		$2.74M Sell
100,000
-74,700
-43% -$3M 0.01% 1694
2016
Q3 		$10.7M Buy
174,700
+94,300
+117% +$2.85M 0.02% 897
2016
Q2 		$1.53M Buy
80,400
+10,400
+15% +$193K ﹤0.01% 1928
2016
Q1 		$1.37M Buy
70,000
+12,400
+22% +$217K ﹤0.01% 2005
2015
Q4 		$2.22M Buy
+57,600
New +$1.87M ﹤0.01% 1853
2015
Q3 		– Sell
-50,000
Closed -$1.52M – 3711
2015
Q2 		$1.52M Hold
50,000
– – ﹤0.01% 2067
2015
Q1 		$664K Hold
50,000
– – ﹤0.01% 2573
2014
Q4 		$724K Buy
+50,000
New +$847K ﹤0.01% 2729
2014
Q1 		– Sell
-80,900
Closed -$1.65M – 3857
2013
Q4 		$1.65M Sell
80,900
-67,500
-45% -$2.01M 0.01% 1951
2013
Q3 		$7.01M Buy
148,400
+112,400
+312% +$4.33M 0.02% 920
2013
Q2 		$1.37M Buy
+36,000
New +$1.29M ﹤0.01% 1805

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's SRPT Position: Q1 2026 in Review

Millennium Management increased its Sarepta Therapeutics (SRPT) stake by 22% in Q1 2026, buying an estimated $4.29M and bringing the position to 1,221,682 shares worth $26.6M. The position accounts for 0.01% of the portfolio, ranked #1312.

Millennium Management first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $120M in Q3 2016. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Millennium Management held 1,221,682 shares of Sarepta Therapeutics worth $26.6M as of Q1 2026.
  • Millennium Management bought 221,573 Sarepta Therapeutics shares in Q1 2026, an estimated $4.29M.
  • Sarepta Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1312 holding.
  • Millennium Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Millennium Management's Sarepta Therapeutics position peaked at $120M in Q3 2016.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.